Attovia Therapeutics, Inc. (Ticker: ATTO US) is an American clinical-stage biopharmaceutical company developing next-generation biologics for immune-mediated diseases using its licensed ATTOBODY nanobody-based platform. Incorporated in Delaware and headquartered in San Carlos, California, the company has no approved products or product-sales revenue.

Attovia plans to list on Nasdaq on August 5, 2026. The company is offering 12.5 million shares at an expected price range of $15.00 to $17.00 per share, seeking to raise approximately $200 million at the $16.00 midpoint. Its estimated market capitalization at the offering is approximately $616 million.

The company’s lead candidate, ATTO-1310, targets IL-31 and completed dosing in a Phase 1 trial involving healthy volunteers and patients with chronic pruritus and atopic dermatitis in the first quarter of 2026. Its pipeline also includes ATTO-2306, a bispecific candidate targeting IL-13 and IL-31, and ATTO-1091, a trispecific candidate being developed for inflammatory bowel disease. Morgan Stanley, Leerink Partners, Citigroup, RBC Capital Markets and LifeSci Capital are managing the offering.